Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV-specific donor-derived T lymphocytes
- Development stage
- Unknown
- Lead developer
- University of Calgary
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Tumor-Infiltrating Lymphocytes (TILs) → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
CMV-VST (University of Calgary) is an investigational cell therapy comprising donor-derived T lymphocytes specifically sensitized to Cytomegalovirus (CMV) antigens. Developed for the treatment of recalcitrant CMV infections in immunocompromised individuals, such as those with primary immunodeficiency, the therapy involves the infusion of virus-specific T cells (VSTs). These cells are designed to recognize and eliminate CMV-infected host cells, thereby restoring cellular immunity against the virus in patients whose own immune systems are unable to control the infection. This specific preparation was utilized in a single-patient, open-label study at the University of Calgary for a patient presenting with CMV viremia and pneumonia.
- Other names
- CMV-specific T cellsDonor-derived T lymphocytesDTL
02
Targets
Cytomegalovirus peptide antigens presented on Human Leukocyte Antigen (HLA)
Beyond the preview
Go deeper on CMV-specific donor-derived T lymphocytes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV-specific donor-derived T lymphocytes.